Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Ruvolo

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Leukemia|July 18, 2024
Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complexM Konopleva, M Milella, P Ruvolo, et al.
Leukemia|March 26, 2011
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathwayA M Martelli, C Evangelisti, W Chappell, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironmentPeter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
Leukemia|April 16, 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyL S Steelman, R A Franklin, S L Abrams, et al.
Biochimica Et Biophysica Acta|May 27, 2014
The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cellsPeter P Ruvolo, Vivian R Ruvolo, Rodrigo Jacamo, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Haematologica|March 17, 2018
Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survivalSteven M Kornblau, Peter P Ruvolo, Rui-Yu Wang, et al.
Haematologica|November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemiaSean M Post, Huaxian Ma, Prerna Malaney, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Leukemia|July 18, 2024
Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complexM Konopleva, M Milella, P Ruvolo, et al.
Leukemia|March 26, 2011
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathwayA M Martelli, C Evangelisti, W Chappell, et al.
Leukemia|October 9, 2021
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequencesAnneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|April 16, 2018
Role of MSC-derived galectin 3 in the AML microenvironmentPeter P Ruvolo, Vivian R Ruvolo, Jared K Burks, et al.
Leukemia|April 16, 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyL S Steelman, R A Franklin, S L Abrams, et al.
Biochimica Et Biophysica Acta|May 27, 2014
The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cellsPeter P Ruvolo, Vivian R Ruvolo, Rodrigo Jacamo, et al.
Annals of Hematology|May 6, 2004
Targeted therapy of AML new conceptsM Andreeff, M Milella, B Z Carter, et al.
Haematologica|March 17, 2018
Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survivalSteven M Kornblau, Peter P Ruvolo, Rui-Yu Wang, et al.
Haematologica|November 4, 2021
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemiaSean M Post, Huaxian Ma, Prerna Malaney, et al.
Blood|September 22, 2020
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG reportFieke W Hoff, Anneke D van Dijk, Yihua Qiu, et al.
Pageof 9